SIG │ Neuropharmacology: Managing Breakthrough Seizures–An Art or Science?

Tuesday, December 7, 2021
-

You may need to log in to view video on this page.

OVERVIEW: 

This Special Interest Group addresses the nuanced management of breakthrough seizures. 

Two-thirds of people with epilepsy experience seizure-freedom with optimization of antiseizure medications. Breakthrough seizures interrupt the seizure-freedom in a subset of these patients and pose the threat of injuries, unemployment, sudden death, and increased health care costs. Management of breakthrough seizures is of paramount importance in maintaining seizure-freedom in medically responsive epilepsy. However, this continues to be a challenge to health care teams. Several factors including medication nonadherence and drug-drug interactions could be the underlying etiology of breakthrough seizures.  

In this SIG, speakers delve deeper into understanding medication nonadherence and utilization of drug monitoring and explore typical to rare drug interactions.  

Case-based learning is used to illustrate discussion points. The speakers prepare a case and create questions for the audience to actively participate using audience polling tools. The use of the poll feature enables presenters and audiences to assess the knowledge level before and after the session as well as their knowledge improvement. 

Learning Objectives:

Following participation in this activity, participants will be able to: 

  • Define non-adherence and classify different types of nonadherence. List strategies to deal with non-adherence 
  • Recognize common, uncommon, and rare drug-drug interactions that might affect level of anti-seizure medications 
  • Analyze the use of anti-seizure drug monitoring while dealing with breakthrough seizures

Program:

SIG Coordinators: Annaporna Bhat, MD, PhD, Mindl Weingarten, PharmD, BCPPS, and Proletta Datta, MD, PhD 

Chair: Annaporna Bhat, MD, PhD 

Antiseizure Medication Non-Adherence | Derek Bauer, MD 

Drug-Dug Interactions – Common, Uncommon, and Rare | Andrea Calvert, PharmD, BCPPS 

Antiseizure Medication Drug Monitoring – Pros, Cons, and Pitfalls | Sasha Alick-Lindstrom, MD 

Activity Type
Special Interest Group
Credit
Non-CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Advanced Practice Providers
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Pharmacists
Scientists/Researchers
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals